Breakthrough in Type 1 Diabetes Treatment
In a groundbreaking medical achievement, researchers have successfully implanted CRISPR-edited pancreas cells into a patient with type 1 diabetes. These cells managed to produce insulin—vital for regulating blood sugar—for several months without requiring the usual immune-suppressing medications. This was possible because the cells, sourced from a deceased donor, were modified to escape detection by the recipient’s immune system.
The study, led by Sana Biotechnology in Seattle, marks a significant step towards finding a lasting cure for a condition that affects millions by forcing them to monitor their blood sugar levels and rely on insulin injections. Aaron Kowalski, CEO of Breakthrough T1D in New York City, expressed optimism, stating, “The preliminary data has definitely lifted the spirits of our community — and it’s a really elegant approach.”
Future Goals and Developments
The next goal is to apply these gene edits to stem cells, guiding their growth into insulin-producing islet cells. Previous small trials with unedited stem cell-derived islets show promise in treating type 1 diabetes, published earlier this year.
However, it’s worth noting that some independent research teams have not replicated the results achieved by Sana. Additionally, the current study involved only one participant who received a small dose of cells for a limited time—insufficient to prove efficacy regarding insulin independence, according to Tim Kieffer from the University of British Columbia.
Kieffer called the immune cloaking aspect “convincing” and a significant advancement toward effective cell therapy without long-term immunosuppression. He previously worked at ViaCyte, a company focused on cell therapy for type 1 diabetes, which was later acquired by Vertex Pharmaceuticals.
Challenges of Current Solutions
Currently, the only way for individuals with type 1 diabetes to eliminate dependency on injected insulin is through the transplantation of cadaveric islet cells. Though this method can restore insulin production for years, it is infrequently performed due to the scarcity of donor pancreases and the necessity for ongoing immune-suppressing drugs, which carry risks of serious side effects.
To combat the limited supply of donors, several companies are exploring stem-cell technologies to produce endless supplies of replacement islets in the lab.
Vertex is making notable strides. In a recent report, the company announced that it had transplanted embryonic stem-cell-derived islets into twelve participants, with ten no longer needing insulin injections after a year. They plan to apply for regulatory approval for this therapy next year.
Meanwhile, scientists at Reprogenix Bioscience in China are also working on producing islets from reprogrammed stem cells derived from patients’ fat tissue, with early signs of effectiveness. Yet, these methods still necessitate anti-rejection drugs either to protect donor cells from immune attacks or combat the autoimmune response affecting even the patient’s own cells.
Innovative Strategies
Sana’s approach aims to eliminate the need for those immunosuppressive drugs entirely. The scientists began with islets from a deceased donor who wasn’t diabetic. Using CRISPR technology, they turned off two genes that usually signal T cells—key players in the immune response—while also using a virus to insert genetic instructions for a protein called CD47. This protein acts as a ‘do not eat me’ signal, helping prevent natural killer cells from attacking the modified cells.
